			Cin Rec'n Printin o 1 MAD 000			
FORM PTO-1390 (REV. 12-2001)	U S DEPARTMENT OF CO	MMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER			
TRA	NSMITTAL LETTER	R TO THE UNITED STATES	148/302			
L	ESIGNATED/ELECT	ED OFFICE (DO/EO/US)	US APPLICATION NO (Ifknown, sec 37 CFR 1 5			
		NG UNDER 35 U.S.C. 371	10/088808			
	ONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED			
PCT/GB00		9/21/2000	9/23/1999			
	ING AGENTS AND METH	ODS				
APPLICANT HALLIWET	(S) FOR DO/EO/US L; Larry; LATHAM, G	eorge; PEEL, Adrian				
Applicant he	ewith submits to the United Sta	ates Designated/Elected Office (DO/EO/US)	the following items and other information:			
		concerning a filing under 35 U.S.C. 371.	and other mioritation.			
		T submission of items concerning a filing u	nder 35 II S.C. 371			
3. This:	s an express request to begin no	ational examination procedures (35 H S C 27				
nems	(3), (6), (3) and (21) indicated	below.	1			
4. X The U	S has been elected by the expirity of the International Application	ration of 19 months from the priority date (A on as filed (35 U.S.C. $371(c)(2)$)	rticle 31).			
a.		only if not communicated by the Internation	al Burgan)			
ъ. [has been communicated by		an Dancauj.			
c. [cation was filed in the United States Receiving	ng Office (RO/US).			
6. An E		e International Application as filed (35 U.S.				
a. [is attached hereto.					
b. [ted under 35 U.S.C. 154(d)(4).	i			
		ernational Aplication under PCT Article 19 (3				
ъ. Г	 a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. 					
с. Г	_					
_	_	er, the time limit for making such amendmen	nts has NOT expired.			
e d. [∑						
_		e amendments to the claims under PCT Artic	le 19 (35 U.S.C. 371 (c)(3)).			
*9.	h or declaration of the inventor	(s) (35 U.S.C. 371(c)(4)).				
10. An En Article	glish lanugage translation of the 36 (35 U.S.C. 371(c)(5)).	e annexes of the International Preliminary Ex	amination Report under PCT			
Items 11 to	20 below concern document(s) or information included:	İ			
1. An I	nformation Disclosure Statemen	at under 37 CFR 1.97 and 1.98.	1			
2 An a	ssignment document for record	ing. A separate cover sheet in compliance w	ith 37 CFR 3.28 and 3.31 is included			
	RST preliminary amendment.	•	and bis I is included.			
_	ECOND or SUBSEQUENT pre	liminary amendment				
_	ostitute specification.	· ····································	j			
_	ange of power of attorney and/o	r address letter	1			
			242 - 125 N G G 1			
		uence listing in accordance with PCT Rule 1				
_		national application under 35 U.S.C. 154(d)(
	ond copy of the English langua	ge translation of the international application	under 35 U.S.C. 154(d)(4).			
0. X Other a. b.	items or information: X Application Dat X Return Receipt					

U.S. APPLICATION NOT THE	8088	P	NTERNATIONAL APPLICATION NO CT/GB00/03616			ATTORNEY'S DO 148/302	CKET NUMBER
21. X The follow	ing fees are sul	omitted:			CAI		PTO USE ONLY
BASIC NATIONAL							
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO							
International prelin USPTO but Intern	ninary examınat ational Search F						
International prelin but international se	ninary examinat arch fee (37 CF	ion fee (3 R 1.445(a	37 CFR 1.482) not paid to (2)) paid to USPTO	USPTO \$740.00			,
International prelin but all claims did n	ninary examınat ot satisfy provis	on fee (3	37 CFR 1.482) paid to US CT Article 33(1)-(4)	SPTO \$710.00			
and all claims satis	fied provisions o	of PCT A	37 CFR 1.482) paid to US rticle 33(1)-(4)	\$100.00			1
					\$	890.00	
months from the ear	liest claimed pri	ority date	or declaration later than (37 CFR 1.492(e)).	20 🕅 30	\$	130.00	,
CLAIMS	NUMBER FI		NUMBER EXTRA	RATE	\$		
Total claims Independent claims		20 =	4	x \$18.00	\$	72.00	
MULTIPLE DEPENI		3 =	1	x \$84.00	\$	84.00	
MOLTIFLE DEPEN				+ \$280.00	\$	280.00 1456.00	
Applicant claim	IU	atus See	F ABOVE CALCULE 37 CFR 1.27. The fees in	LATIONS =	\$	1430.00	
are reduced by	1/2.			+	\$		
D : C C014			SU	BTOTAL =	\$	1456.00	
months from the earl	10.00 for furnish	ning the E ority date			\$		
			TOTAL NATIO		\$ ·	1456.00	
Fee for recording the accompanied by an a	enclosed assign ppropriate cover	ment (37 sheet (37	CFR 1.21(h)). The assig 7 CFR 3.28, 3.31). \$40.0	nment must be 0 per property +	\$		
			TOTAL FEES EN	CLOSED =	\$ -	1456.00	
						nt to be funded:	\$
					С	harged:	\$
a. X A check in t	he amount of	§ <u>14</u>	56.00 to cover the	above fees is enclos	ed.		
b. Please charge my Deposit Account No in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.							
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 01-0265. A duplicate copy of this sheet is enclosed.							
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card.							
information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been thet, a potition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending evalus.							
SEND ALL CORRESPONDENCE TO							
W. Thad Adams, III							
ADAMS, SCHWARTZ & EVANS, P.A.							
2180 Two Wachovia Center W. Thad Adams, III							
301 S. Tryon Street NAME							
Charlotte, N	C 28282			29,037			
				REGISTRA	JI NOI I	JMBER	l l

IC1D Rec'd PCT/PTO 2 1 MAR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

HALLIWELL, Larry, et al.

INT'L APL. NO.:

PCT/GB00/03616

INT'L FILING DATE:

21 September 2000

FOR:

STERILISING AGENTS AND METHODS

BOX PCT

Assistant Commissioner for Patents Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

After the assignment of a serial number and prior to the initial examination of the above-identified patent application, please make the following amendments:

IN THE SPECIFICATION:

Amend the specification by inserting after the title, but before the first sentence on page 1:

--This application is a national stage application, according to Chapter II of the Patent Cooperation Treaty. This application claims the priority date of September 23, 1999 for International Patent Application No. PCT/GB00/03616. --

IN THE CLAIMS:

Please cancel original claims 1 - 11 and enter new claims 12-34 as follows:

"The state of the
APPLICANT: INT'L APL. NO.:

HALLIWELL et al. PCT/GB00/03616

- - 12. A sterilizing block for use in an airspace within a container, comprising:
- (a) a sterilizing composition comprising a sulphur dioxide activating compound wherein moisture absorbed by the block reacts with the sulphur dioxide activating compound to form sulphur dioxide;
 - (b) a water-soluble organic acid; and
 - (c) a corresponding water soluble salt of the organic acid.
- 13. A sterilizing block according to claim 12, wherein the water soluble organic acid and the corresponding water soluble salt of the organic acid each comprise 2-5 percent by weight of the total weight of the sterilizing composition.
- 14. A sterilizing block according to claim 12, wherein the water soluble organic acid comprises 1 to 3 carboxylic acid groups, and the corresponding salt is selected from the group consisting of a magnesium salt, a sodium salt, and a potassium salt.
- 15. A sterilizing block according to claim 12, wherein the block is selected from the group consisting of a solid gel block, a tablet of consolidated powder and a tablet of consolidated granules.

APPLICANT: INT'L APL, NO.: HALLIWELL et al. PCT/GB00/03616

- 16. A sterilizing block according to claim 12, wherein the sulphur dioxide activating compound is a metabisulphite.
- 17. A sterilizing block according to claim 16, wherein the metabisulphite is selected from the group consisting of sodium metabisulphite or potassium metabisulphite.
- 18. A sterilizing block according to claim 12, wherein the container is a diaper pail or medical hazardous waste disposal container.
- 19. A sterilizing block for use in an airspace within a container, comprising:
- (a) a sterilizing composition comprising a sulphur dioxide activating compound wherein moisture absorbed by the block reacts with the sulphur dioxide activating compound to form sulphur dioxide; and
 - (b) a hygroscopic compound.
- 20. A sterilizing block according to claim 19, wherein the hygroscopic compound is a hygroscopic alkylbenzene-sulphonate.

APPLICANT: INT'L APL. NO.: HALLIWELL et al. PCT/GB00/03616

- 21. A sterilizing block according to claim 19 or 20, wherein the hygroscopic compound comprises 1-2.5 percent by weight of the total weight of the sterilizing composition.
- 22. A sterilizing block according to claim 19, wherein the block is selected from the group consisting of a solid gel block, a tablet of consolidated powder and a tablet of consolidated granules.
- 23. A sterilizing block according to claim 19, wherein the sulphur dioxide activating compound is a metabisulphite.
- 24. A sterilizing block according to claim 23, wherein the metabisulphite is selected from the group consisting of sodium metabisulphite or potassium metabisulphite.
- 25. A sterilizing block according to claim 19, wherein the container is a diaper pail or medical hazardous material disposal container.

APPLICANT: INT'L APL. NO.: HALLIWELL et al. PCT/GB00/03616

- 26. A method of sterilizing an airspace within a container, comprising the steps of:
 - (a) providing:
- (i) a sterilizing composition comprising a sulpher dioxide activating compound wherein moisture within the container reacts with the sulphur dioxide activating compound to form sulphur dioxide;
 - (ii) a water-soluble organic acid; and
 - (iii) a corresponding water soluble salt of the organic acid;
 - (b) forming the sterilizing composition into a block; and
- (c) placing the block into the container, the airspace within which is to be sterilized.
- 27. A method according to claim 26, wherein the water soluble organic acid and the corresponding water soluble salt of the organic acid each comprise 2-5 percent by weight of the total weight of the sterilizing composition.
- 28. A method according to claim 26, wherein the water soluble organic acid comprises 1 to 3 carboxylic acid groups, and the corresponding salt is selected from the group consisting of a magnesium salt, a sodium salt, and a potassium salt.

APPLICANT: INT'L APL. NO.: HALLIWELL et al. PCT/GB00/03616

- 29. A method according to claim 26, wherein the step of forming the composition into a block comprises the step of forming the composition into an block selected from the group consisting of a solid gel block, a tablet of consolidated powder and a tablet of consolidated granules.
- 30. A method according to claim 26 wherein the sulphur dioxide activating compound is a metabisulphite.
- 31. A method according to claim 30, wherein the metabisulphite is selected from the group consisting of sodium metabisulphite or potassium metabisulphite.
- 32. A method according to claim 26, wherein the step of placing the block into a container comprises the step of placing the block into a diaper pail or medical hazardous material disposal container.
- 33. A method of sterilizing an airspace within a container, comprising the steps of:
 - (a) providing:

APPLICANT:

HALLIWELL et al.

INT'L APL. NO.:

PCT/GB00/03616

Page 7

 (i) a sterilizing composition for use in an airspace within a container, the composition comprising a sulpher dioxide activating compound wherein moisture absorbed by the block reacts with the sulphur dioxide activating compound to form sulphur dioxide;
 and

- (ii) a hygroscopic compound;
- (b) forming the sterilizing composition into a block; and
- (c) placing the block into the container, the airspace within which is to be sterilized.

34. A method according to claim 22, wherein the water soluble organic acid and the corresponding water soluble salt of the organic acid each comprise 2-5 percent by weight of the total weight of the sterilizing composition. - -

REMARKS

Pursuant to 37 C.F.R. §1.121(c)(ii), a marked-up copy of the claim amendments is included with this Preliminary Amendment and labeled as "Exhibit A." It is believed that this application is now in condition for allowance. Such action at an early date is respectfully requested.

Respectfully submitted.

W. Thad Adams, III

Reg. No. 29,037

APPLICANT: HALLIWELL et al. INT'L APL. NO.: PCT/GB00/03616

Page 8

W. Thad Adams, III ADAMS, SCHWARTZ & EVANS, P.A. 2l80 Two Wachovia Center 30I S. Tryon Street Charlotte, NC 28282

Tel: (704) 375-9249 Fax: (704) 375-0729

E-Mail: wta@adamspat.com

File No. 148/302

EXHIBIT A

AMENDED CLAIMS - MARKED-UP COPY
(U.S. National Phase of International Application No. PCT/GB00/03616)

Please cancel claims 1 - 11.

WO 01/21224

1

PCT/GB00/03616

STERILISING AGENTS AND METHODS

This invention relates to sterilising agents, in particular to those which, when activated, form sulphur dioxide, and also to a method of sterilising substantially enclosed airspaces.

It is well known to use sterilising agents which form sulphur dioxide to sterilise enclosed spaces. Such agents have been used in a wide variety of applications including sterilisation of fermentation bins and sanitary bins.

In the case of fermentation bins, granules or tablets of the sterilising agent are dissolved rapidly in water in the fermentation bin, which quickly releases large quantities of sulphur dioxide for fast sterilisation.

In the case of sanitary bins, where there is only a small amount of moisture in the air and/or materials inside the bin, it is usual to add a portion of the sterilising agent in powder or granule form. The powder or granules have a large surface area which enables activation by the available moisture to form a sufficient amount of sulphur dioxide for sterilisation.

25

30

20

10

The powder or granules are usually added by sprinkling them on the bottom of the container, either from a porous container or by opening individual sachets of sterilising agent and pouring the powder or granules into the container.

However, when the sterilising agent is applied in this manner a certain amount of dust from the powder or

PCT/GB00/03616

granules is generated, which can be harmful to a user if inhaled. People with bronchial afflictions, such as asthma, may be especially vulnerable to adverse effects from the dust.

5

10

15

20

30

Some sterilising agents for sanitary bins, enclosed spaces and the like are delivered as powder or granules in porous sachets, which allow moisture to penetrate the sachet and sulphur dioxide generated to diffuse out into the bins. However this method of delivery does not prevent all the dust generated by the powder or granules inside the sachet from escaping into the surrounding atmosphere, creating a hazard to the user. Such dust and/or powder release is hazardous to people, particularly those with bronchial complaints, for example asthmatics. Furthermore, the porous sachets are prone to tearing.

It is therefore an object of preferred embodiments of the present invention to provide a sterilising agent which forms sulphur dioxide upon activation with available moisture, in a form which does not produce harmful dust during insertion into an enclosed space.

It is a further object of preferred embodiments of the 25 present invention to provide a sterilising agent which releases sulphur dioxide over a prescribed period of time for efficient sterilisation, for a particular application.

Therefore, according to a first aspect of the present invention there is provided a sterilising block comprising a sterilising composition for use in an airspace within a container, the sterilising composition comprising a sulphur dioxide activating compound, wherein moisture

absorbed by the block reacts with the sulphur dioxide activating compound to form sulphur dioxide, and wherein the sterilising composition further comprises a water soluble organic acid and a corresponding water soluble salt of the organic acid.

Suitably the water soluble organic acid and water soluble salt of the organic acid are water soluble at ambient temperature.

10

20

25

The water soluble organic acid and corresponding salt act to inhibit the release of sulphur dioxide from the sterilising composition. While the applicant is not limited by any theoretical explanation, it is believed the water soluble acid and salt act as a buffer to inhibit formation of sulphur dioxide, thus prolonging the term of action of the composition. Thus the term "water-soluble" relates to the organic acid and corresponding salt being sufficiently soluble in water at ambient temperature to act as a buffer, in the composition of the present invention, as moisture is absorbed by the block.

Preferably the water soluble organic acid and corresponding salt maintain the sterilising block, as moisture is absorbed, at a pH of not more than 7.5, more preferably at a pH not more than 6.5. Preferably the water soluble organic acid and corresponding salt maintain the sterilising block, as moisture is absorbed, at a pH of not less than 3.5, more preferably not less than 4.5 and most preferably not less than 5.5. A preferred pH range is 5.5. - 6.5.

4

Suitably the organic acid is a water soluble organic acid comprising 1 to 3 carboxylic acid groups, or anhydrides thereof. Alternatively the organic acid may be ascorbic acid.

5

Preferred water soluble organic acids include lactic acid, malic acid, fumaric acid, pyruvic acid, succinic acid, ascorbic acid and citric acid, of which citric acid and malic acid are most preferred.

10

30

Suitably the organic acid and corresponding salt each comprise 1-12 carbon atoms, preferably 1-9 carbon atoms, more preferably 1-6 carbon atoms.

15 The corresponding salts of the water soluble acid include magnesium, sodium and potassium salts. Preferred corresponding salts of malic acid or citric acid are sodium malate and sodium citrate respectively.

Suitably the water soluble organic acid comprises at least 1%wt of the total weight of the sterilising composition, more preferably at least 2% wt, as added to the sterilising composition. Preferably the water soluble organic acid comprises no more than 10% wt of the total weight of the sterilising composition, more preferably no more than 5% wt.

Suitably the corresponding salt of the organic acid comprises at least 1%wt of the total weight of the sterilising composition, more preferably at least 2%wt.

Preferably the corresponding salt of the organic acid comprises no more than 10% wt of the total weight of the

sterilising composition, more preferably no more than 5% wt.

Thus the preferred range of the water soluble organic acid and the corresponding salt, combined, is 4-10%wt of the total weight of the sterilising composition.

Most preferably the water soluble organic acid and the corresponding salt of the organic acid comprise equal amounts in the total weight of the sterilising composition.

All amounts described herein are a %wt of the total weight of the sterilising composition as added in the form of raw ingredients. It is understood that once the sterilising block absorbs moisture, the relative portions of the individual components of the composition may change, for example the organic acid and/or salt may dissociate in solution, and the proportion of sulphur dioxide activating compound will decrease on evolution of sulphur dioxide.

15

20

25

30

According to a second aspect of the present invention there is provided a sterilising block comprising sterilising composition for use in an airspace within a container, the sterilising composition comprising sulphur dioxide activating compound, wherein moisture absorbed by the block reacts with the sulphur dioxide activating compound to form sulphur dioxide and wherein the sterilising composition further comprises а hygroscopic compound.

It is believed that the hygroscopic compound increases rate of release of sulphur dioxide from sterilising agent by increasing the rate of uptake of moisture into the sterilising block. The hygroscopic compound enables the sterilising composition manufactured in a block with limited surface area for use in an airspace which is low in moisture, as it will enable the block to absorb a sufficient amount of moisture from the air and/or waste materials within the airspace to activate the sulphur dioxide activating compound.

Preferably the hygroscopic compound is a hygroscopic alkylbenzenesulphonate, or dialkylbenzenesulphonate However, other types of hygroscopic material may be used.

15

10

A preferred dialkylbenzenesulphonate is diisopropylbenzenesulphonate.

Preferably the hygroscopic compound comprises at least 0.5%wt of the total weight of the sterilising agent, more preferably at least 1%wt.

Preferably the hygroscopic compound comprises no more than 5%wt of the total weight of the sterilising agent, more preferably no more than 2.5% wt.

Thus a preferred range for the hygroscopic compound is 1-2.5%wt of the total weight of the sterilising composition.

30

25

The block should be such that it produces an insubstantial amount, and preferably no, harmful dust when inserted into the airspace.

PCT/GB00/03616

Suitably the block is a tablet or solid gel block. Preferably it is a tablet of consolidated powder or granules.

5

10

20

25

30

The sulphur dioxide may, preferably, be in gaseous form and/or may dissolve in water or an aqueous medium present in the air space, and so act, in the form of sulphurous acid or a salt thereof, as a liquid sterilising composition. It will be understood that further volatile compounds of sulphur may be formed, in addition to sulphur dioxide.

Preferably the sterilising composition comprises a polyglycol compound, more preferably a polyethylene glycol compound.

Suitably the polyglycol compound comprises at least 0.5%wt of the total weight of the sterilising composition, preferably at least 1%wt, as added to the sterilising composition.

Preferably the polyglycol compound comprises no more than 10%wt of the total weight of the sterilising composition, more preferably no more than 5% wt, as added to the sterilising composition.

Suitably the sulphur dioxide activating compound is a metabisulphite, preferably sodium metabisulphite or potassium metabisulphite.

20

25

Preferably the sulphur dioxide activating compound comprises at least 50% wt of the total weight of the sterilising composition, more preferably at least 60% wt.

Suitably the sulphur dioxide activating compound comprises no more than 95% wt of the total weight of the sterilising composition, preferably no more than 90% wt, more preferably no more than 80% wt.

The sterilising composition may additionally comprise one or more ancilliary ingredients, including a fragrance, a colouring compound, talc, sodium chloride, and a filler.

Suitably each block is supplied in its own sealed space. For example it may be individually wrapped or provided in "blister pack" form.

Alternatively blocks may be packaged together, preferably in a sealed container containing, separately, a hygroscopic agent (for example silica qel) preferentially to absorb atmospheric moisture, and so prevent premature activation of the sulphur dioxide activating compound. Such a hygroscopic agent may also be employed when each block is supplied in its own sealed Thus, the sterilising blocks may be kept in an inactive form until needed, prolonging their shelf-life and subsequent utility.

Preferably the container is generally enclosed.

Preferably the container is used for deposit or storage of contaminated, or more preferably biological materials, for example biological soils, microorganisms, or biological waste products.

Preferably the container is a sanitary bin.

Alternatively, the container may be a medical dressing container, a nappy bin, a used sharps bin, a post box, a refrigerator, a body bag or a container used for the disposal or containment of any contaminated or, preferably, biological waste.

10 When the container is a food refrigerator, the block is preferably placed in a non-airtight container to prevent accidental contact with food contained within the refrigerator.

The invention also provides a method of sterilising an airspace comprising the use of a block as described and defined above.

The following examples better serve to illustrate preferred embodiments of the present invention.

Example 1

Sodium chloride

A tablet of compressed granules was prepared using the following ingredients in the proportions given:

18.0

% wt of total weight of composition
Citric acid 2.5
Sodium citrate 2.5
Polyethylene glycol (PEG6000) 2.0
Talc 1.0
Sodium metabisulphite 73.2
Perfume 0.8

The dry ingredients were mixed together, with the exception of the perfume, which was subsequently sprayed onto the mixed ingredients. The composition was then granulated and fed into a die wherein the granules were compressed into tablet form by a press having a force of 8 tons.

Example 2

The method of Example 1 was repeated for the following composition:

	% wt of total weight of	composition
	Corn starch	1.5
	Sodium di-isopropylbenzene sulphonate	1.0
15	Polyethylene glycol (PEG 6000)	2.0
	Talc	1.0
	Sodium metabisulphite	75.7
	Perfume	0.8
	Sodium chloride	18.0

20

25

Both compositions are of utility in effectively sterilising an airspace within a container. The composition of Example 1 is particularly useful for containers in which there is a relatively large amount of moisture or moist contaminant present, with the buffering action of the organic acid and corresponding salt components moderating the release of sulphur dioxide.

The composition of Example 2 is particularly useful in sterilising airspaces within containers that contain a relatively low amount of moisture, or contain contaminated materials that are relatively dry.

The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.

11

All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.

15 Each feature disclosed in this specification (including any accompanying claims, abstract drawings), may be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic 20 series of equivalent or similar features.

The invention is not restricted to the details of the foregoing embodiment(s). The invention extend to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.

25

10

CLAIMS

- A sterilising block comprising a sterilising composition for use in an airspace within a container, the sterilising composition comprising a sulphur dioxide activating compound, wherein moisture absorbed by the block reacts with the sulphur dioxide activating compound to form sulphur dioxide, and wherein the sterilising composition further comprises a water soluble organic acid and a corresponding water soluble salt of the organic acid.
- A sterilising block as claimed in claim 1, wherein the water soluble organic acid and the corresponding water
 soluble salt of the organic acid each comprise 2-5% wt of the total weight of the sterilising composition.
- A sterilising block as claimed in claim 1, wherein the water soluble organic acid comprises 1 to 3 carboxylic
 acid groups, and the corresponding salt is selected from the group consisting of a magnesium, sodium and potassium salt.
- 4. A sterilising block comprising a sterilising composition for use in an airspace within a container, the sterilising composition comprising a sulphur dioxide activating compound, wherein moisture absorbed by the block reacts with the sulphur dioxide activating compound to form sulphur dioxide, and wherein the sterilising composition further comprises a hygroscopic compound.

20

25

- 5. A sterilising block as claimed in claim 4, wherein the hygroscopic compound is a hygroscopic alkylbenzenesulphonate.
- 6. A sterilising block as claimed in claims 4 or 5, wherein the hygroscopic compound comprises between 1-2.5%wt of the total weight of the sterilising composition.
- 7. A sterilising block as claimed in any preceding claims, wherein the block is a solid gel block or is a tablet of consolidated powder or granules.
- 8. A sterilising block as claimed in any preceding claim, wherein the sulphur dioxide activating compound is a metabisulphite.
 - 9. A sterilising block as claimed in claim 8, wherein the metabisulphite is sodium metabisulphite or potassium metabisulphite.
 - 10. A sterilising block as claimed in any preceding claim, wherein the container is a sanitary bin, a medical dressing container, a nappy bin, a used sharps bin, a post box, a refrigerator, a body bag or a container used for the disposal or containment of any biological waste.
 - 11. A method of sterilising an airspace comprising the use of a block of any of claims 1 to 10.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 29 March 2001 (29.03.2001)

PCT

(10) International Publication Number WO 01/21224 A1

(51) International Patent Classification7: 9/012, 11/00

A61L 2/23,

- (21) International Application Number: PCT/GB00/03616
- (22) International Filing Date:

21 September 2000 (21.09.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

9922415.6

- 23 September 1999 (23.09.1999) GB
- (71) Applicant (for all designated States except US): ALLIED BIO CORPORATION LIMITED [GB/GB]; Providence Works Nield Street, Oldham, Lancashire OL8 1QG (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HALLIWELL, Larry [GB/GB]; 10 Hillmount, Hollins Estate, Dukinfield, Cheshire SK16 5HT (GB). LATHAM, George [GB/GB]; 1 Brooklet Close, Springhead, Oldham OLA 5UB (GB). PEEL, Adrian [GB/GB]; 210 Turf Lane, Royton CL2 6EU (GB).

- (74) Agents: PIDGEON, Robert, John et al.; Appleyard Lees, 15 Clare Road, Halifax HX1 2HY (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STERILISING AGENTS AND METHODS

(57) Abstract: A sterilising agent is provided for use in a generally enclosed airspace within a container, the sterilising block comprising a sterilising agent in the form of a sulphur dioxide activating compound which reacts with moisture in the airspace to release sulphur dioxide, wherein the sterilising agent further comprises a moderating compound, which inhibits or accelerates the release of sulphur dioxide from the block. The use of a block provides a sterilising composition which does not produce harmful dust during insertion into an airspace.

148/302

COMPLETE IF KNOWN

Halliwell

PTO/SB/01 (10-01)
Approved for use through 10/31/2002 OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

DECLARATION FOR UTILITY OR

DESIGN PATENT APPLICATION Attorney Docket Number

First Named Inventor

any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 156, including for continuation-in-part applications, material information which became available between the filling date of the prior application and the national or PCT international filling date of the continuation-in-part application. I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant orreeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant preeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is	(37 CFR ⁻	Application Number	10 /	<u>088,808</u>				
Submitted of Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required) As the below named inventor, I hereby declare that: My residence, mailing address, and critizenship are as stated below next to my name. I believe I am the original and first inventor of the subject matter which is claimed and for which a patent'is sought on the invention entitled STERITISING AGENTS AND METHODS (Title of the Invention) the specification of which is attached hereto OR was filed on (MM/DD/YYYY) 03/21/2002 as United States Application Number or PCT International Application Number 10/088,808 and was amended on (MM/DD/YYYY) (if applicable). Thereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above. Lacknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or FCT interestly claim foreign priority became available between the filing date of the prior application and the national or FCT interestly claim foreign priority certified specification, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or FCT interestly claim foreign priority certified cells, or any PCT international application having a filing Date (MM/DD/YYYY) Prior Foreign Application Country Frior Foreign Application on which priority is alment. Prior Foreign Application on which priority is alment.	Declaration X	Declaration	Filing Date	03/2	1/2002			
As the below named inventor, I hereby declare that: My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original and first inventor of the subject matter which is claimed and for which a patent'is sought on the invention entitled STERFILISTING AGENTS AND METHODS (Title of the Invention) the specification of which is attached hereto OR Was filed on (MM/DD/YYYY) 03/21/2002 as United States Application Number or PCT International Application Number 10/088,808 and was amended on (MM/DD/YYYY) (if applicable). Thereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above. Lackhowledge the duty to disclose information which is material to patentability as defined in 37 CFR 156, including for continuation-in-part applications, material information which became available between the filing date of the continuation-in-part applications, material information which became available between the filing date of the continuation-in-part applications. The continuation of the proof application of the prior application of the number of year inventor's or plant inventor's or plant inventor's or plant inventor's or plant which designated at least one county other than the United States of America, listed below and have also identified below, by checking the box, any foreign application or priority or pri	Submitted OR	Submitted after Initial	Art Unit					
My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original and first inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled STERILISING AGENTS AND METHODS (Title of the Invention) the specification of which is attached hereto OR was filed on (MM/DD/YYYY) 03/21/2002 as United States Application Number or PCT International Application Number 10/088,808 and was amended on (MM/DD/YYYY) (if applicable). I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above. Lacknowledge the duty to disclose information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application. Hereby claim foreign priority benefits under 5 U.S.C. 119(4) or (f), or 365(a) of any PCT international application which designated as the least one country other than the United States of America, listed below and have also identified below, by checking the box any ordering national for patent inventor's or plant preders rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box any ordering application on which priority is aligned. Prior Foreign Application Country Foreign Filing Date (MM/DD/YYYY) Not Claimed YES NO		(37 ČFR 1.16 (e))	Examiner Name					
I believe I am the original and first inventor of the subject matter which is claimed and for which a patent'is sought on the invention entitled STERTITISING AGENTS AND METHODS (Title of the Invention) the specification of which is attached hereto OR was filed on (MM/DD/YYYY) 03/21/2002 as United States Application Number or PCT International Application Number 10/088,808 and was amended on (MM/DD/YYYY) (if applicable). Thereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above. Lacknowledge the duty to disclose information which is material formation which is material to praintability as defined in 37 CFR 156, including for continuation-in-part application. International filing date of the continuation-in-part application. International filing date of the continuation-in-part application. International filing date of the continuation-in-part application. International splication which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box any foreign application on which priority is alarined. Prior Foreign Application Country Foreign Filing Date (MM/DD/YYYY) Not Claimed YES NO	As the below named inventor, I he	reby declare that:	-					
STERIETSING AGENTS AND METHODS (Title of the Invention) the specification of which is attached hereto OR Application Number 10/088,808 and was amended on (MM/DD/YYYY) (if applicable). Thereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the pror application and the national or PCT international filing date of the continuation-in-part applications moreagn prorist) benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant preceder's rights certificate(s), or 365(s) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application or patent, inventor's or plant preceder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is laimed Prior Foreign Application Number(s) Country Foreign Filing Date (MM/DD/YYYY) Not Claimed YES NO	My residence, mailing address, and o	citizenship are as stated belo	w next to my name.					
the specification of which is attached hereto OR X was filed on (MM/DD/YYYY) O3/21/2002 as United States Application Number or PCT International Application Number 10/088,808 and was amended on (MM/DD/YYYY) (if applicable). Thereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above. Application Number for the continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international infining date of the continuation-in-part application. Ihereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant proceeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant proceeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is laimed Prior Foreign Application Country Foreign Filing Date Priority Certified Copy Attached? YES NO Country Foreign Filing Date Priority Certified Copy Attached? YES NO	I believe I am the original and first inv	entor of the subject matter w	hich is claimed and for wh	ich à patent'is sou	ight on the invention entitled			
the specification of which is attached hereto OR X was filed on (MM/DD/YYYY) 03/21/2002 as United States Application Number or PCT International Application Number 10/088,808 and was amended on (MM/DD/YYYY) (if applicable). I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above. Lacknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 156, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant oreder's rights certificate(s), or 363(s) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant oreder's rights certificate(s), or 363(s) of any PCT international application having a filing date before that of the application on which priority is international application having a filing date before that of the application on which priority is international application for patent, inventor's or plant oreder's rights certificate(s), or 365(s) or 36								
is attached hereto OR X was filed on (MM/DD/YYYY) O3/21/2002 as United States Application Number or PCT International Application Number 10/088,808 and was amended on (MM/DD/YYYY) (if applicable). Thereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above. Lacknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 156, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application. Thereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant oreader's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant or patent		(Title of the In	vention)					
Application Number 10/088,808 and was amended on (MM/DD/YYYY) (if applicable). Thereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 156, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application. Thereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant preder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant oreder's rights certificate(s), or 365(b) of any foreign application for patent, inventor's or plant oreder's rights certificate(s), or 365(b) of any foreign application for patent, inventor's or plant oreder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed Prior Foreign Application Number(s) Country Foreign Filing Date (MM/DD/YYYY) Not Claimed Priority Certified Copy Attached? Not Claimed YES NO	the specification of which							
Application Number 10/088,808 and was amended on (MM/DD/YYYY) (if applicable). I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1 56, including for continuation-in-part applications, material information which became available between the filling date of the prior application and the national or PCT international filling date of the continuation-in-part application. Thereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant preeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant preeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed Prior Foreign Application Country Foreign Filing Date (MM/DD/YYYY) Rot Claimed Priority VES NO Certified Copy Attached? YES NO	is attached hereto							
I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1 56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application. I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant preceder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant preceder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed Prior Foreign Application Rumber(s) Country Foreign Filing Date (MM/DD/YYYY) Not Claimed Priority YES NO Certified Copy Attached? YES NO	03/04/0000							
acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application. I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant priority or part or priority defends and have also identified below, by checking the box, any foreign application for patent, inventor's or plant priority or patent, inventor's or plant priority is calciumed. Prior Foreign Application Prior Foreign Application Country Country Foreign Filing Date (MM//DD/YYYY) Rot Claimed Priority Not Claimed Priority YES NO	Application Number 10/088,808 and was amended on (MM/DD/YYYY) (if applicable).							
applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application. Thereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant priority or graph continuation and priority or plant priority in the priority of the priority of the priority is certificate. Prior Foreign Application Number(s) Country Priorign Filing Date (MM//DD/YYYY) Residual or patent, inventor's or plant priority or patent, inventor's or plant priority is certificate. Priorign Application Number(s) Country Foreign Filing Date (MM//DD/YYYY) Certified Copy Attached? YES NO	I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.							
Prior Foreign Application Number(s) Prior Foreign Application Number(s) Country Country Por international application which designated at least one country other than the United America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant brieder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed Prior Foreign Application Number(s) Country Foreign Filing Date (MM/DD/YYYY) Not Claimed YES NO	l acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1 56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.							
Number(s) Country (MM/DD/YYYY) Not Claimed YES NO	I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed							
		Country						
Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto			(<u>-</u>					
	Additional foreign application nur	nbers are listed on a supplen	nental priority data sheet F	TO/SB/02B attach	ned hereto			

100

200

PTO/SB/01 (10-01)
Approved for use through 10/31/2002 OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

DECLARATION — Utility or Design Patent Application

Direct all correspondence to X Customer Number or Bar Code Label OR Correspondence address below						
Name						
Address						
City		State		ZIP		
	Telephone			Fax		
I hereby declare that all statements made herein of m are believed to be true; and further that these statem made are punishable by fine or imprisonment, or both validity of the application or any patent issued thereon	nents were made wit n, under 18 U.S.C. 10	h the knowle	edge that willful false	statements and the like so		
NAME OF SOLE OR FIRST INVENTOR :	A petition h	as been fi	led for this unsigr	ned inventor		
Given Name (first and middle [f apy]) Larry		Family Na or Surnan				
Inventor's Signature				Date 6.8.02		
Residence: City Dukinfield GB3	State Chesh	ire co	untry GB	Citizenship GB		
Mailing Address 10 Hillmount, Hollins Estate						
City Dukinfield	State Chesh	ire _{ZIP}	SK16 5HT	Country GB		
NAME OF SECOND INVENTOR:	A petition has	s been file	d for this unsigne	d inventor		
Given Name (first and middle (if any)) George Family Name or Surname Latham						
Inventor's Signature	-			Date 5 08 02		
Residence: City Springhead 653	State Oldha	m Coi	untry GB	Citizenship GB		
Mailing Address 1 Brooklet Close						
City Springhead	State Oldha	m ZIP	OL4 5UB	Country GB		
X Additional inventors are being named on the 1:	supplemental Additio	nal Inventor(s) sheet(s) PTO/SB/0	02A attached hereto		

[Page 2 of 2]

Please type a plus sign (+) inside this box

300

PTO/SB/02A (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

DECLARATION

ADDITIONAL INVENTOR(S) Supplemental Sheet Page ___ of ___

Name of Additional Joint Inventor, if a		A petition has been filed for this unsigned inventor				
Given Name (first and middle [if any])			Family Name or Surname			
Adrian 0		Peel!				
Inventor's Signature		<		Date \$ /8/2002		
Residence: City Royton & B3	State		Country GB	Citizenship GB		
Mailing Address 210 Turf Lane						
Mailing Address				.	,	
City Royton	State		ZIP OL2 6EU	Count	y GB	
Name of Additional Joint Inventor, if a	ny:		A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any	/])		Family Name or Surname			
Κ.						
Inventor's Signature					Date	
Residence: City	State		Country		Citizenship	
Mailing Address						
Mailing Address						
City	State		ZIP	Cou	ntry	
Name of Additional Joint Inventor, if a	ny:	П	A petition has been filed			
Given Name (first and middle [if any])			Family Name or Surname			
, , , , , , , , , , , , , , , , , , ,						
Inventor's Signature Date					Date	
Residence: City State			Country		Citizenship	
Mailing Address						
Mailing Address						
City State			ZIP Country		untry	

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time, you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED. FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Washington, DC 20231.